European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
Graham
Ian
I
Department of Cardiology, The Adelaide and Meath Hospital, Tallaght, Dublin, Ireland. ian.graham@amnch.ie
Atar
Dan
D
Borch-Johnsen
Knut
K
Boysen
Gudrun
G
Burell
Gunilla
G
Cifkova
Renata
R
Dallongeville
Jean
J
De Backer
Guy
G
Ebrahim
Shah
S
Gjelsvik
Bjørn
B
Herrmann-Lingen
Christoph
C
Hoes
Arno
A
Humphries
Steve
S
Knapton
Mike
M
Perk
Joep
J
Priori
Silvia G
SG
Pyorala
Kalevi
K
Reiner
Zeljko
Z
Ruilope
Luis
L
Sans-Menendez
Susana
S
Op Reimer
Wilma Scholte
WS
Weissberg
Peter
P
Wood
David
D
Yarnell
John
J
Zamorano
Jose Luis
JL
Walma
Edmond
E
Fitzgerald
Tony
T
Cooney
Marie Therese
MT
Dudina
Alexandra
A
Vahanian
Alec
A
Camm
John
J
De Caterina
Raffaele
R
Dean
Veronica
V
Dickstein
Kenneth
K
Funck-Brentano
Christian
C
Filippatos
Gerasimos
G
Hellemans
Irene
I
Kristensen
Steen Dalby
SD
McGregor
Keith
K
Sechtem
Udo
U
Silber
Sigmund
S
Tendera
Michal
M
Widimsky
Petr
P
Zamorano
Jóse Luis
JL
Altiner
Attila
A
Bonora
Enzo
E
Durrington
Paul N
PN
Fagard
Robert
R
Giampaoli
Simona
S
Hemingway
Harry
H
Hakansson
Jan
J
Kjeldsen
Sverre Erik
SE
Larsen
mogens Lytken
mL
Mancia
Giuseppe
G
Manolis
Athanasios J
AJ
Orth-Gomer
Kristina
K
Pedersen
Terje
T
Rayner
Mike
M
Ryden
Lars
L
Sammut
Mario
M
Schneiderman
Neil
N
Stalenhoef
Anton F
AF
Tokgözoglu
Lale
L
Wiklund
Olov
O
Zampelas
Antonis
A
D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000235:genetics / Q000503:physiopathology / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy; D005260:Female; D020022:Genetic Predisposition to Disease; D019983:Guideline Adherence; D006293:Health Promotion; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood / Q000150:complications; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy; D008019:Life Style; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D009043:Motor Activity; D009747:Nutritional Physiological Phenomena; D009765:Obesity / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D050177:Overweight; D011322:Primary Prevention / Q000592:standards*; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects; D016540:Smoking Cessation; D013315:Stress, Psychological / Q000150:complications / Q000628:therapy; D016896:Treatment Outcome
D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D008055:Lipids